Jagsonpal Pharma

Jagsonpal Pharma reported a 'flattish' Q3 FY26 performance with revenue at INR 73 crores, which was below management's expectations. This was attributed to a strategic recalibration of field operations and brand repositioning under new leadership, aimed at improving long-term growth. The company also faced headwinds from its RPM market growing slower at 3-3.5% compared to the overall IPM growth of approximately 8%.

Despite the Q3 slowdown, the company demonstrated resilient performance over the nine-month period. Revenue grew 6% year-on-year to INR 223 crores, and Profit After Tax (PAT) improved by 12.5% year-on-year to INR 35.9 crores. Q3 PAT also saw a 10% YoY growth to INR 12.5 crores, with PAT margins improving by 180 basis points to 17.1%, reflecting operational resilience and underlying brand strength.

Management expressed confidence in achieving double-digit growth from Q4 FY26 onwards, aiming for 50% more than the industry growth rate, which is projected at 7.5-8.5%. Key growth drivers include price increases, new product launches, and new SKU introductions, expected to contribute 50% of the growth, with the remainder from volume growth. Product launches in high-growth therapeutic areas are anticipated by the end of H1 next fiscal year.

The company undertook a deliberate recalibration of field operations, including strategic repositioning of brand teams and optimization of field deployment. While these changes caused near-term disruption and elevated attrition, the transition is largely complete, with signs of improved team stability and operational momentum. The focus going forward^⏳ is on enhancing field productivity and strengthening brand investments to drive consistent execution.

Jagsonpal Pharma accounted for an additional past service cost of INR 2.1 crores as an exceptional item^📎 in Q3 FY26 due to the new labor code. Management clarified that this is a one-time^📎 cumulative impact related to past gratuity and leave encashment calculations. They anticipate very little impact on overall employee remuneration costs going forward^⏳, with applicability expected from April 1, 2026.

The company's free cash balance increased by INR 15.2 crores in Q3, reaching INR 176 crores. Management is actively seeking accretive M&A opportunities but notes that current asset valuations are high. They reiterated a disciplined approach to M&A, ensuring any acquisition creates value for shareholders. If suitable M&A opportunities are not found, the company is committed to returning capital to shareholders in an appropriate format.

The successful integration of the Yash Pharma acquisition was highlighted, with the acquired portfolio contributing more than expected to growth. The increase in depreciation since March 2024 was clarified to be primarily due to the depreciation of intangibles (trademarks, etc.) acquired as part of the Yash Pharma deal, rather than manufacturing assets, aligning with the company's asset-light model.

As part of its strategic realignment, Jagsonpal Pharma rationalized some small, long-tail SKUs that were inefficiently deploying capital. This move, representing approximately 1.5-2% of the top line, aims to free up capital and allow for greater focus on larger, high-potential brands, contributing to improved overall business health and growth.